SDEV Stablecoin Development (SDEV) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001389545
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about SDEV
Insiders, 180 days
-$80.8K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
1 filing
Largest: 9.9% of the class
Stablecoin Development insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Stablecoin Development Corp insiders sold a net $80.8K of stock across 3 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 22,668,516 shares held after it.
- 2 other insiders sold within 30 days.
Insider activity: Chief Executive Officer Kazley Michael John sold about $26.9K of SDEV on Jun 15, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 22,668,516 shares held after it.
- 2 other insiders sold within 30 days.
Insider activity: Insider Framework Ventures Management LLC sold about $26.9K of SDEV on Jun 15, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.1% of the 22,668,516 shares held after it.
- 2 other insiders sold within 30 days.
Insider activity: Chief Executive Officer R01 Capital Manager LLC sold about $26.9K of SDEV on Jun 15, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$80.8K over 180 days
-$80.8K of it by a 10%+ holder
more than 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-6.4% year over year
below 63% of Pharma & Biotech
Margin
-6449.0% net margin
below 98% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.9% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 60% of Pharma & Biotech
The situation: each line is one rule over one dataset
Sky Frontier Foundation disclosed a 5%+ stake (9.9%) in the last six months.
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch SDEV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-82.3%12M
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SDEV: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in SDEV
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Sky Frontier Foundation
Activist 13D · 2026-05-27
9.9%
SDEV planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Mr. Hall
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$1.3M
$436.8K
-91%
n/a
2024
$365.2K
$366.5K
$220.2K
-99%
n/a
2023
$364.1K
$358.9K
$190.8K
-90%
n/a
2022
$365.0K
$111.5K
$259.3K
-92%
n/a
2021
$795.5K
$490.9K
$528.7K
-46%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $80.8K sold by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
SDEV financials
Revenue growth
-6.4%
XBRL, annual
Net margin
-6449.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM SDEV
| FY Dec 2025 | $2.8M |
| FY Dec 2024 | $9.8M |
| FY Dec 2023 | $14.7M |
| FY Dec 2022 | $14.4M |
| FY Dec 2021 | n/a |
| Jun 2026 | $2.2M |
| Mar 2026 | $2.5M |
| Dec 2025 | n/a |
| Sep 2025 | $521.0K |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $2.3M |
| Sep 2024 | $2.4M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM SDEV
| FY Dec 2025 | -22,289% |
| FY Dec 2024 | -73.8% |
| FY Dec 2023 | -65.5% |
| FY Dec 2022 | -73.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,862% |
| Mar 2026 | +22,428% |
| Dec 2025 | n/a |
| Sep 2025 | -248.2% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -52.5% |
| Sep 2024 | -49.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SDEV
| FY Dec 2025 | -$8.4M |
| FY Dec 2024 | -$7.5M |
| FY Dec 2023 | -$4.2M |
| FY Dec 2022 | -$6.8M |
| FY Dec 2021 | -$9.2M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -$2.3M |
| Jun 2025 | -$2.5M |
| Mar 2025 | -$1.3M |
| Dec 2024 | -$1.7M |
| Sep 2024 | -$2.4M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term debt only, 2019-06-30 (85 months older than the period end); equity 2026-06-30
Debt to equity SDEV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.50x |
| FY Dec 2022 | 0.16x |
| FY Dec 2021 | 0.16x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | n/a |
| Sep 2025 | 1.49x |
| Jun 2025 | 0.39x |
| Mar 2025 | 0.27x |
| Dec 2024 | n/a |
| Sep 2024 | 1.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-7.47x
TTM operating cash flow over long-term debt only, 2019-06-30 (85 months older than the period end)
Cash flow to debt SDEV
| FY Dec 2025 | -5.10x |
| FY Dec 2024 | -4.53x |
| FY Dec 2023 | -2.50x |
| FY Dec 2022 | -4.02x |
| FY Dec 2021 | -5.56x |
| Jun 2026 | -7.47x |
| Mar 2026 | -5.39x |
| Dec 2025 | -5.10x |
| Sep 2025 | -4.73x |
| Jun 2025 | -4.82x |
| Mar 2025 | -4.14x |
| Dec 2024 | -4.53x |
| Sep 2024 | -3.88x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-190.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SDEV
| FY Dec 2025 | n/a |
| FY Dec 2024 | -453.6% |
| FY Dec 2023 | -139.0% |
| FY Dec 2022 | -102.4% |
| FY Dec 2021 | -51.8% |
| Jun 2026 | -190.4% |
| Mar 2026 | -118.7% |
| Dec 2025 | n/a |
| Sep 2025 | +297.4% |
| Jun 2025 | +183.2% |
| Mar 2025 | +115.7% |
| Dec 2024 | -453.6% |
| Sep 2024 | -249.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-186.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SDEV
| FY Dec 2025 | -10,127% |
| FY Dec 2024 | -116.0% |
| FY Dec 2023 | -75.8% |
| FY Dec 2022 | -52.5% |
| FY Dec 2021 | -29.7% |
| Jun 2026 | -186.3% |
| Mar 2026 | -90.8% |
| Dec 2025 | -10,127% |
| Sep 2025 | +88.1% |
| Jun 2025 | +61.4% |
| Mar 2025 | +48.1% |
| Dec 2024 | -116.0% |
| Sep 2024 | -121.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SDEV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-52.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SDEV
| FY Dec 2025 | -199.2% |
| FY Dec 2024 | -276.6% |
| FY Dec 2023 | -48.6% |
| FY Dec 2022 | -88.2% |
| FY Dec 2021 | -53.8% |
| Jun 2026 | -52.7% |
| Mar 2026 | +18.7% |
| Dec 2025 | -199.2% |
| Sep 2025 | -417.3% |
| Jun 2025 | -340.5% |
| Mar 2025 | -203.4% |
| Dec 2024 | -276.6% |
| Sep 2024 | -130.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing SDEV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$45.3M
market value at close 2026-10-23 on 2026-07-27 shares, plus long-term debt only, 2019-06-30 (85 months older than the period end), minus cash 2026-06-30
Enterprise value SDEV
| FY Dec 2025 | $3.5B |
| FY Dec 2024 | $15.9M |
| FY Dec 2023 | $227.3M |
| FY Dec 2022 | $22.2B |
| FY Dec 2021 | $104.6B |
| Jun 2026 | $23.2M |
| Mar 2026 | $22.9M |
| Dec 2025 | $3.5B |
| Sep 2025 | $36.6M |
| Jun 2025 | $13.2M |
| Mar 2025 | $10.3M |
| Dec 2024 | $15.9M |
| Sep 2024 | $17.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-24.4%
TTM free cash flow over market value at close 2026-10-23
FCF yield SDEV
| FY Dec 2025 | -0.2% |
| FY Dec 2024 | -51.2% |
| FY Dec 2023 | -1.8% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -43.4% |
| Mar 2026 | -22.5% |
| Dec 2025 | -0.2% |
| Sep 2025 | -21.0% |
| Jun 2025 | -47.3% |
| Mar 2025 | -39.9% |
| Dec 2024 | -51.2% |
| Sep 2024 | -38.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing SDEV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $9.8M | $14.7M | $14.4M |
| Gross profit | n/a | $6.5M | $6.1M | $7.8M |
| Operating income | -$8.4M | -$7.4M | -$4.1M | -$14.4M |
| Net income | -$630.8M | -$7.2M | -$9.6M | -$10.6M |
| Operating cash flow | -$8.4M | -$7.5M | -$4.1M | -$6.7M |
| Cash | $8.0M | $430.0K | $2.9M | $5.4M |
| Dividends paid | $4.8M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
SDEV Stock Sonar score 5/7 axes
Find similar shapesCompareSDEV ranks highest on financial health (50th percentile) and growth (37th), and lowest on risk and compliance (16th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SDEV filings, in plain words
Are Stablecoin Development insiders buying or selling SDEV?
In the 180 days to 2026-10-27, Stablecoin Development insiders were net sellers, a net $80.8K across purchases and sales reported on Form 4, by 3 sellers.
Read the full summary
In the 180 days to 2026-10-27, Stablecoin Development insiders were net sellers of SDEV, a net $80.8K across purchases and sales reported on Form 4 by 3 sellers. Most of that figure, $80.8K, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 9.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
